Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.60 |
| ▸ | LPL | P06858 | 3/20 | 0.60 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204921 | 0.83 | ENPP2 (0.73) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL12281931 | 0.83 | CA2 (0.35) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL15459223 | 0.81 | CA2 (0.60) | CA2LPLLIPGENPP2CA1 | |
| Tolyl Boronic Acid SCHEMBL5600068 | 0.75 | CA2 (1.00) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL16301136 | 0.75 | ENPP2 (0.55) | CA2ENPP2CA1TSHRCA4 | |
| Tolyl Boronic Acid SCHEMBL129197 | 0.75 | CA2 (1.00) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL14407594 | 0.75 | CA2 (0.61) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL12282435 | 0.73 | CA2 (0.39) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL806835 | 0.73 | CA2 (0.78) | CA2LPLLIPGENPP2CA1 | |
| SCHEMBL9946022 | 0.73 | CA2 (0.39) | CA2LPLLIPGCA1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CA2 3510/4885LPL 2017/4885LIPG 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.